Reference : Absence of regulator of G-protein signaling 4 does not protect against dopamine neuro...
Scientific journals : Article
Life sciences : Biotechnology
Life sciences : Multidisciplinary, general & others
Human health sciences : Neurology
Systems Biomedicine
http://hdl.handle.net/10993/31416
Absence of regulator of G-protein signaling 4 does not protect against dopamine neuron dysfunction and injury in the mouse 6-hydroxydopamine lesion model of Parkinson's disease
English
Ashrafi, Amer [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
Garcia, Pierre [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
Kollmus, Heike []
Schughart, Klaus []
del Sol Mesa, Antonio [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
Buttini, Manuel [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
Glaab, Enrico mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
In press
Neurobiology of Aging
Elsevier
Yes (verified by ORBilu)
International
0197-4580
1558-1497
New York
NY
[en] Parkinson's disease ; mouse model ; histopathology ; behavior ; neuroprotection ; target validation ; substantia nigra ; RGS4 ; regulator of G-protein signaling
[en] Regulator of G-Protein Signaling 4 (RGS4), a member of the RGS family of proteins that inactivate G-proteins, has gained interest as a potential drug target for neurological disorders, such as epilepsy and Parkinson’s disease (PD). In the case of PD, the main current option for alleviating motor symptoms are dopamine replacement therapies, which have limitations because of side effects, and reduced effectiveness over the long term. Research on new non-dopaminergic PD drug targets has indicated that inhibition of RGS4 could be an effective adjuvant treatment option. The effectiveness of RGS4 inhibition for an array of PD-linked functional and structural neuroprotection endpoints has not yet been demonstrated. Here, we use the 6-Hydroxydopamine (6-OHDA) lesioning model of the nigrostriatal pathway in mice to address this question. We observe, using a battery of behavioral and pathological measures, that mice deficient for RGS4 are not protected from 6-OHDA induced injury, and show enhanced susceptibility in some measures of motor function. Our results suggest that inhibition of RGS4 as a non-dopaminergic target for PD should be approached with caution.
Luxembourg Centre for Systems Biomedicine (LCSB): Biomedical Data Science (Glaab Group)
Fonds National de la Recherche - FnR
Researchers ; Professionals ; Students
http://hdl.handle.net/10993/31416
10.1016/j.neurobiolaging.2017.06.008
http://www.sciencedirect.com/science/article/pii/S019745801730204X
The original publication is available at http://www.sciencedirect.com/science/article/pii/S019745801730204X
FnR ; FNR5782168 > Enrico Glaab > ExPDIENT > Exploring Parkinson?s Disease Inhibitor Efficacy on a Non-dopaminergic Target > 01/12/2013 > 31/05/2016 > 2013

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Limited access
RGS4_neurobiology_of_aging_author_postprint.pdfPublisher postprint1.02 MBRequest a copy

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.